Tandem Diabetes Care to Announce Third Quarter 2022 Financial Results on November 2, 2022

Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) plans to announce its third quarter 2022 results post-market close on November 2, 2022. A conference call and webcast, scheduled for 4:30 PM ET, will discuss the financial and operational results. Investors can access the live webcast via the Investor Center on their website. An archived version will be available for 30 days following the event.

As a prominent insulin delivery and diabetes technology firm, Tandem continues to innovate with products like the t:slim X2 insulin pump featuring Control-IQ technology.

Positive

• Scheduled release of Q3 2022 results may attract investor interest.
• The t:slim X2 insulin pump with Control-IQ technology is a significant product, enhancing treatment for diabetes.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2022 results after the financial markets close on Wednesday, November 2, 2022. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2022 financial and operating results.

A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section. To access the call by phone, please use this link (Registration Link) and you will be provided with dial-in details, including a personal pin.

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care and Control-IQ are trademarks registered in the U.S. and/or other countries and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005999/en/

Media Contact:

Steve Sabicer

714-907-6264

ssabicer@thesabicergroup.com

Investor Contact:

Susan Morrison

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.

FAQ

What date will Tandem Diabetes Care release its Q3 2022 results?

Tandem Diabetes Care will release its Q3 2022 results on November 2, 2022.

What time is the conference call for Tandem Diabetes Care's Q3 results?

The conference call will be held at 4:30 PM ET on November 2, 2022.

Where can I listen to the Q3 2022 results webcast for Tandem Diabetes Care?

The webcast can be accessed on Tandem Diabetes Care's Investor Center website.

What is the significance of the t:slim X2 insulin pump?

The t:slim X2 insulin pump features Control-IQ technology, offering advanced insulin delivery solutions for diabetes management.